Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.

Abstract: Provided herein is a prohealing piezoelectric coating and the method of making and using the same.

Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.

Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.

Abstract: The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes.

Abstract: This invention involves two fields of photoelectron information materials and pharmaceuticals, especially refers to the self-assembly of conducting photoluminescence nanomedicine crystals and thin films and their preparation processes. In the invention, self-assembling unitary, binary, ternary and quaternary complexes of an antioxidase antioxidant, an agonist of the ?-adrenergic receptors, an agonist of the P2-purinergic receptors and an antagonist of benzalkonium-typed calcium channels is to employ an interaction of inelastic electron tunneling, which possesses photoelectron properties of inelastic electron tunneling and photoluminescence with the central wavelength ˜500 nm and the wavelength wide ˜200 nm in the size-controlled square or cubic geometrical complexes. The invention is not only beneficial for drug discovery targeted disease mechanisms, but also profitable for inventions of photoelectron sensing new materials.

Abstract: A method for treating a disease, particularly asthma and anaphylactic shock, comprises administering to a subject in need thereof an effective amount of an EC-SOD protein or a vector having a polynucleotide encoding thereof.

Abstract: The present invention provides a composition for improving skin conditions, containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient. The present invention contains the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient inside a nanoliposome comprising hydrogenated lecithin as a constituent component, and the particle size is 50-250 nm. The composition of the present invention reduces wrinkles and alleviates atopic dermatitis. In addition, the present invention provides a method for improving skin conditions, comprising the step of administering a composition containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient to a subject.

Abstract: Aspects of embodiments may include methods for automated enzymatic detection of glucose-6-phosphate dehydrogenase (G6PD) activity. Aspects of embodiments may include methods for enzymatic detection of G6PD activity in droplets in oil. Aspects of embodiments may include a system including a droplet actuator. Aspects of embodiments may include a treatment method.

Abstract: A method for treating an angiogenesis-mediated eye disease, includes administering to a subject in need thereof an effective amount of EC-SOD protein, or a vector having a polynucleotide encoding the EC-SOD protein, to treat angiogenesis-mediated eye diseases.

Abstract: A reagent measuring a glycated protein, comprising a protease and a protein of any one of [1] to [4] below: [1] a protein comprising the amino acid sequence represented by SEQ ID NO:1; [2] a protein comprising an amino acid sequence with one to ten amino acid deletions, substitutions, or additions in the amino acid sequence represented by SEQ ID NO:1, and having fructosyl peptide oxidase activity; [3] a protein comprising an amino acid sequence having 99% or higher homology to the amino acid sequence represented by SEQ ID NO:1, and having fructosyl peptide oxidase activity; and [4] a protein having fructosyl peptide oxidase activity, which is encoded by an expression plasmid harbored by the Escherichia coli XL1-Blue MRF? strain deposited under Accession No. FERM BP-11026.

Abstract: A nutritional composition comprising by weight: between 0.05 and 30% selenium-enriched yeast; between 1 and 90% yeast beta-glucan; between 0.5 and 60% Vitamin C; and between 0.5 and 40% Vitamin E. The composition features anti-oxidative, anti-aging, cancer-preventing, and immune-stimulating properties.

Abstract: The present invention relates to nucleic acids coding for and capable of expressing a rod-derived cone viability factor (RdCVF) and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting an RdCVF, and methods of treatment.

Abstract: The invention discloses a pharmaceutical composition comprising recombinant human superoxide dismutase (rhS-OD) for preventing or treating one or more adverse reactions caused by treatment with an EGFR inhibitor in a subject.

Abstract: Composition for the removal of biofilms present on a substrate, comprising at least one detergent component comprising at least one sequestering agent and at least one agent that is simultaneously a wetting and a dispersing agent, and at least one enzymatic component containing at least one protease, at least one laccase and at least one polysaccharidase

Abstract: The invention provides fusion protein constructs comprising a functional mitochondrial protein and methods of treating mitochondrial disorders by the fusion proteins and compositions thereof.

Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.

Abstract: According to this invention, compositions and methods for increasing the extent of penetration of a biologically active substance into the tissues and organs are proposed, the methods comprising administration of the biologically active substance in combination with one or more chaotropic agents, e.g., ammonium sulfate.

Abstract: Compositions comprising Glutathione Reductase (GSSG-r) and Oxidized Glutathione (GSSG) or pharmaceutically acceptable salts thereof for pharmaceutical use as antiviral and antibacterial agents and for the protection against the toxicity of free radicals and in particular radicals produced by the radiolysis of cellular water are provided. Methods of making and using such compositions are also provided.

Abstract: The present invention provides a method for reducing an allergic response and treating or preventing an allergic disease, comprising administering a subject in need thereof a therapeutically effective amount of the active ingredient for the treatment or the prevention of allergic diseases, wherein the active ingredient is glyceraldehyde-3-phosphate Dehydrogenase (G3PDH) or the functional variant or fragment thereof. The G3PDH can be isolated from Lactobacillus gasseri PM-A0005 (deposited under Budapest Treaty in the China Center for Type Culture Collection (CCTCC) with Deposit No: M 207039), as well as extract, fraction, and sub-fraction thereof.

Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.

Abstract: Method for preparing an oxidized polysaccharide-protein composition, by (a) oxidizing a polysaccharide with an oxidizing agent to form an oxidized polysaccharide where less than 20% of the oxidized units are comprised of alpha-hydroxy aldehyde units, (b) reacting the oxidized polysaccharide with a protein to form a composition comprising an oxidized polysaccharide-protein conjugate, and (c) maintaining the oxidized polysaccharide-protein conjugate composition by placing it in an environment where the temperature is less than 8° C. The oxidized polysaccharide and the protein are conjugated via one or more imine bonds, the oxidized polysaccharide-protein composition is soluble in aqueous solvent, and the composition is capable of releasing the protein.

Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.

Abstract: This invention relates to improvements to medical devices such as biosensors containing proteins such as oxidoreductases, for example oxidase and/or peroxidase enzymes. More generally it relates to novel compositions containing proteins which are stabilised to ionising radiation.

Abstract: The present invention relates to collagen hydrolysate and the use thereof for treating and/or preventing cellulite.

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: The present invention is directed to 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with elevated blood uric acid levels, such as hyperuricemia or gout. The invention is also directed to the tosylate salt of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide.

Abstract: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic acids. The compositions containing said substances showed antifungal activity and mycelium growth and fungi ascospore germination inhibiting activity, amongst them Mycosphaerella fijiensis, primary pathogenic agent causing black Sigatoka disease in banana and plantain crop fields.

Abstract: A method of treatment of a human or animal body surface infection, particularly a fungal infection, comprises applying an aqueous liquid to the infected body surface, e.g. nail region, followed by applying a dressing comprising a source of hydrogen peroxide. Also provided is a combination of the liquid and dressing for use in the method.

Abstract: Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation.

Abstract: The present invention relates to specially selected catalase enzymes and their use in reducing hydrogen peroxide in applications, and particularly in aseptic packaging applications.

Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.

Abstract: The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme formulations include at least one histaminase and various methods of treatment of physical conditions, such as inflammation, allergy, histamine intolerance, and intestinal cancer.

Abstract: The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme.

Abstract: A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.

Abstract: The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.

Abstract: The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.

Abstract: Methods and compositions for protecting muscarinic receptor(s) in a subject from at least one carcinogenic or toxic metal by administration of a pyrophosphate analog. Methods and compositions for preventing at least one disease induced or caused by metals compromising the function of muscarinic receptors in a subject by administration of a pyrophosphate analog. Methods and compositions for reducing toxic action of metal ions and for reducing poisoning by metals by administering a pyrophosphate analog.

Abstract: Methods and compositions for protecting and treating a muscarinic receptor in an animal or plant from bacterial, fungal, algo or algae infections through administration of at least one pyrophosphate analog.

Abstract: The present invention provides a method of biosynthesizing a recombinant protein containing the biologically active peptide, the pharmaceutical composition containing the recombinant protein as well as the preparation of the recombinant protein. Simply speaking the consecutively multiple copies of the bioactive peptide are replaced in the amino acid sequence of a recombinant protein (so called peptide-protein). Then, a high concentration and high yield of the peptide-protein containing the consecutively multiple copies of the bioactive peptide is produced by the biosafety and edible strain of yeast without any endotoxin contamination.

Abstract: This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin.

Abstract: An aliphatic polyester polymer for stent coating is described.

Abstract: Methods and compositions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds.

Abstract: The present invention relates to cosmetic or dermatological compositions containing PQQ or its esters, methods of treating or promoting skin changes by topical application of these compositions, and methods of synthesis of PQQ esters. The PQQ ester-containing compositions of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance. When included in a topical composition, the PQQ esters of the present invention have an antioxidant effect that is useful in treating a skin change.

Abstract: Verticillin A is found to be a potent inhibitor of histone methyltransferases, selective for G9a, GLP, SUV39H1, SUV39H2, MLL1, and NSD2. Methods of using Verticillin A are provided. The Verticillin A can be synthetically produced or it can be isolated from natural sources. Methods if inhibiting one or more histone methyltransferases are provided. In addition, methods are provided for treating diseases or disorders related to overexpression of one or more histone methyltransferases. Exemplary diseases and disorders to be treated include cancer, asthma, HIV, and progeria.

Abstract: Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.

Abstract: What is provided is a method of treating a patient having a tumor comprising administering an effective amount of adenosine deaminase, preferably polyalkylene oxide conjugated, to a patient in need thereof.

Abstract: Provided in the present invention is an application for PRDX2 and/or PRDX6 in the preparation of a pharmaceutical composition to treat or prevent damage, aging or diseases resulting from an increase in reactive oxygen species (ROS).

Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.

Abstract: The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like.